| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/30/2006 | US7053059 Dialysis solutions with reduced levels of glucose degradation products |
| 05/30/2006 | US7053054 Purified LH |
| 05/30/2006 | US7053034 Targeted controlled delivery compositions activated by changes in pH or salt concentration |
| 05/30/2006 | US7052913 capsules comprising biocompatible silica sol-gel matrices that encapsulate chemical intermediates or prodrugs that convert when contacted with tissues and/or fluids; grafting encapsulated L-amino acid decarboxylase in the brain to convert L-dopa to dopamine for prophylaxis of Parkinson's disease |
| 05/30/2006 | US7052861 Graphitic nanotubes in luminescence assays |
| 05/30/2006 | US7052719 Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
| 05/30/2006 | US7052717 Storage stable thyroxine active drug formulations and methods for their production |
| 05/30/2006 | US7052715 Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
| 05/30/2006 | US7052711 Nitric oxide-producing hydrogel materials |
| 05/30/2006 | US7052704 Comprises fatty acid-conjugated products with disulfide linkage to proteins/peptides for delivery to cells; increases absorption and prolongs blood and tissue retention |
| 05/30/2006 | US7052702 comprises a light-chain or a heavy-chain fragment of a Pseudonomas neurotoxin with a proteolytically active enzyme domain; N-acetylgalactosamine-binding lectins; to inhibit the release of neurotransmitters from neurons thereby reducing and/or preventing transmission of afferent pain signals |
| 05/30/2006 | US7052689 Preventing viral replication in cells; obtain cells, incubate with viricide, monitor cells for reduced viral activity |
| 05/30/2006 | US7052686 Pegylated interleukin-10 |
| 05/30/2006 | US7052680 aerosols containing antiparkinsons drugs benzotropine, pergolide, amantadine, deprenyl and ropinerole, that have been heated on a solid support such as foil and condensed by passing through a flow of air |
| 05/30/2006 | US7052679 thin film of drugs; heating; dispensing as aerosol condensation |
| 05/30/2006 | US7052678 Particles for inhalation having sustained release properties |
| 05/30/2006 | US7052672 Stabilized radiopharmaceutical compositions |
| 05/30/2006 | CA2288970C Use of microparticles having a protein and an antibody adsorbed thereon for preparing a pharmaceutical composition for intranasal administration |
| 05/30/2006 | CA2264718C Solid coprecipitates for enhanced bioavailability of lipophilic substances |
| 05/30/2006 | CA2260637C Free-flowable, directly compressible starch as binder, distinegrant and filler for compression tablets and hard gelatine capsules |
| 05/30/2006 | CA2184899C Highly reactive esters of carboxy polysaccharides and novel carboxy polysaccharides derived therefrom |
| 05/30/2006 | CA2181715C Liquid ophthalmic sustained release delivery system |
| 05/30/2006 | CA2085831C Polymers and oligomers of bile acid derivatives, process for their preparation and their use as pharmaceuticals |
| 05/26/2006 | WO2006055954A2 Steroid formulation and methods of treatment using same |
| 05/26/2006 | WO2006055632A2 Pharmaceutical manufacturing process for heat sterilized glucocorticoid suspensions |
| 05/26/2006 | WO2006055447A2 Nanoparticles having a magnetic core and a cationic organo-silane coating for the delivery of oligonucleotides |
| 05/26/2006 | WO2006055264A1 Formulations, methods of production and uses of fgf-20 |
| 05/26/2006 | WO2006054589A1 Medicinal composition, medicinal preparation, and combination preparation |
| 05/26/2006 | WO2006054315A1 Nonaqueous liquid parenteral aceclofenac formulation |
| 05/26/2006 | WO2006054059A1 Neutralising antibody molecules having specificity for human il-17 |
| 05/26/2006 | WO2006053761A2 Modified plant gums for preparations of active ingredients |
| 05/26/2006 | WO2006053430A1 Sirna silencing of apolipoprotein b |
| 05/26/2006 | WO2006053383A1 Bioactive compositions |
| 05/26/2006 | WO2006020852A3 Pharmaceutical composition and method for treating neurodegenerative disorders |
| 05/26/2006 | WO2006008173A3 Pharmaceutical formulations for inhalation |
| 05/26/2006 | WO2005121369A3 Rna-containing microvesicles and methods therefor |
| 05/26/2006 | WO2005115339A3 Composition for enhancing absorption of a drug and method |
| 05/26/2006 | WO2005110438A3 Methods and products related to the intracellular delivery of polysaccharides |
| 05/26/2006 | WO2005099769A3 Novel g-csf conjugates |
| 05/26/2006 | WO2005082336A3 Kit comprising a plaster that optionally contains an active ingredient and an agent that prevents skin irritation |
| 05/26/2006 | WO2005059118A3 Stem cell targeting using magnetic particles |
| 05/26/2006 | WO2005058360A3 Radiation therapy and medical imaging using uv emitting nanoparticles |
| 05/26/2006 | WO2005053727A3 Pharmaceutical compositions for bioactive peptide agents |
| 05/26/2006 | WO2005039641A3 Biomacromolecule polymer conjugates |
| 05/26/2006 | CA2587411A1 Sirna silencing of apolipoprotein b |
| 05/26/2006 | CA2586213A1 Formulations, methods of production and uses of fgf-20 |
| 05/26/2006 | CA2585316A1 Benzothiazole formulations and use thereof |
| 05/26/2006 | CA2584222A1 Neutralising antibody molecules having specificity for human il-17 |
| 05/25/2006 | US20060111553 Novel thrombin inhibitors, the preparation and use thereof |
| 05/25/2006 | US20060111323 Use of polysiloxanes having quaternary ammonium groups as formulation auxiliaries, and compositions comprising them |
| 05/25/2006 | US20060111277 treating fungal infections; improved thermal stability and water solubility; releasing carbohydrate upon dispersion of the complex in water |
| 05/25/2006 | US20060111275 Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy alkylene glycols |
| 05/25/2006 | US20060111274 Methods and compositions for enhancing transport across biological membranes |
| 05/25/2006 | US20060111273 Water soluble paclitaxel derivatives |
| 05/25/2006 | US20060110520 Active oxygen eliminator derived from natural substance and use thereof |
| 05/25/2006 | US20060110517 Novel compositions comprising carotenoids |
| 05/25/2006 | US20060110465 Compositions addressing inflammation and/or degenerative disorders |
| 05/25/2006 | US20060110463 Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin |
| 05/25/2006 | US20060110460 dissolving active principle in water; emulsifying resulting solution of active principle with d,l-lactide-co-glycolide matrix copolymer, emulsifying first emulsion in external aqueous phase containing surfactant, viscosity-enhancing agent, osmotic agent, extraction-evaporation to form microspheres |
| 05/25/2006 | US20060110458 Sustained release drug carrier |
| 05/25/2006 | US20060110443 toxic or potent core is incorporated into the dosage form via three-dimensional printing, as a solution, solubilization or suspension of solid particles in liquid, rather than by the more conventional handling and compressing of dry powder; allows greater bioavailability |
| 05/25/2006 | US20060110433 Adhesive patch |
| 05/25/2006 | US20060110426 Cohesive coprecipitates of sulfated polysaccharide and fibrillar protein and use thereof |
| 05/25/2006 | US20060110423 polyglycolic acid or polylactic acid or glycolic acid-lactic acid copolymer as biocompatible polymer having dispersed therein an active agent such as exendin-4; antidiabetic agent |
| 05/25/2006 | US20060110413 Novel Molecules dervied from noraporphine |
| 05/25/2006 | US20060110410 Recombinant toxin fragments |
| 05/25/2006 | US20060110409 Targeted agents for nerve regeneration |
| 05/25/2006 | US20060110400 Immunogenic conjugates |
| 05/25/2006 | US20060110382 For treating a disease medicated by TNF alpha including acute and chronic immune and immunoregulatory disorders and rheumatoid or osteo-arthritis |
| 05/25/2006 | US20060110381 comprising a continuous, biocompatible liquid phase, a solid phase comprising porous or non-porous particles of a biocompatible polymer suitable for use in hemostasis and which are substantially insoluble in the liquid phase, and sterile thrombin |
| 05/25/2006 | US20060110379 Linkage of agents using microparticles |
| 05/25/2006 | US20060110356 Ophthalmic drug delivery system using polymer micelle |
| 05/25/2006 | US20060110333 Composition for nasal absorption |
| 05/24/2006 | EP1659143A1 Temperature-responsive hydrogel |
| 05/24/2006 | EP1659142A1 Polyhydroxyalkanoate compositions having controlled degradation rates |
| 05/24/2006 | EP1658860A1 Drug compositions comprising anticholinergics and EGFR kinase inhibitors |
| 05/24/2006 | EP1658856A1 Exendins for glucagon suppression |
| 05/24/2006 | EP1658852A1 Oral pharmaceutical preparation containing ibandronat |
| 05/24/2006 | EP1658848A1 Formulations comprising ecteinascidin and a disaccharide |
| 05/24/2006 | EP1658772A2 Receptor specific transepithelial transport of immunogens |
| 05/24/2006 | EP1658285A1 Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
| 05/24/2006 | EP1658273A1 Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
| 05/24/2006 | EP1658103A1 Methods and devices for the treatment of intervertebral discs |
| 05/24/2006 | EP1658089A2 Compositions for treating pathologies that necessitate suppression of gastric acid secretion |
| 05/24/2006 | EP1658079A1 Multivitamin syrup for children or young adults |
| 05/24/2006 | EP1658057A2 Microparticles |
| 05/24/2006 | EP1658047A1 Spray-dried amorphous powder with a low residual moisture and excellent storage stability |
| 05/24/2006 | EP1658046A1 Mucoadhesive composition comprising polyacrylate and chemoattractant |
| 05/24/2006 | EP1658029A1 Transdermal hormone delivery system: compositions and methods |
| 05/24/2006 | EP1487496B1 Test system for evaluating the compatibility of biologically active substances with copolymers |
| 05/24/2006 | EP1471944B1 Pharmaceutical composition which improves in vivo gene transfer |
| 05/24/2006 | EP1469886B1 Lyophilized pharmaceutical composition of propofol |
| 05/24/2006 | EP1466614A4 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon |
| 05/24/2006 | EP1383480A4 Lipid-comprising drug delivery complexes and methods for their production |
| 05/24/2006 | EP1267836B1 Process for the preparation of accelerated release formulations using compressed fluids |
| 05/24/2006 | EP1263801B1 Tissue bulking and coating compositions |
| 05/24/2006 | EP1263413B1 Method of preparing solid dispersions |
| 05/24/2006 | EP1227848B1 Method for linking molecular substances |
| 05/24/2006 | EP1212410B1 Dna encoding the human serine protease eos |
| 05/24/2006 | EP1196151B1 Transdermal therapeutic system for administering a calcium antagonist |